视神经管减压术治疗视神经挫伤20例分析

目的：报告视神经挫伤行视神经管减压术的治疗效果。方法：手术治疗限定于外伤后不超过1月且无严重颅脑损伤及无严重全身疾病者。采用局麻筛蝶窦入口法,手术前后常规用糖皮质激素及神经生长因子。结果：20例术前无光感16例,术后1周视力有光感及手动以上12例,占75％;术前视力在手动－0．04以内4例,术后视力均提高。术后随访3个月除2例外视力均有提高,最好达到0．3。结论：视神经挫伤病期不超过1月虽视力已无光感也不应放弃行视神经管减压术。     

Cag A Hp抗体测定与消化性溃疡和慢性胃炎的关系

目的 :探讨幽门螺杆菌细胞毒素相关基因蛋白 (CagA)抗体与消化性溃疡和慢性胃炎的关系。方法 :对132例消化性溃疡和慢性胃炎Hp幽门螺杆菌阳性的 118例病例 ,用ELISA方法进行CagA抗体检测。结果 :10 9例消化性溃疡中 ,CagA抗体阳性 90例 ,阳性率 82 .6 % ;9例慢性胃炎中 ,CagA抗体阳性 5例 ,阳性率 5 5 .6 %。消化性溃疡组CagA阳性率明显高于慢性胃炎组 (P <0 .0 1)。结论 :CagA抗体检测在消化性溃疡中有一定意义     

胫骨平台骨折的关节镜下分型

目的 分析胫骨平台骨折的关节镜下分型及处理原则。方法 在关节镜下观察88例胫骨平台骨折的病理类型,进行复位和内固定治疗,并随访远期疗效。结果 根据关节镜下的病理特征将胫骨平台骨折分为8个类型,关节镜监视下处理骨折,平均随访4年,总优良率87．2％。结论 关节镜下分型有助于胫骨平台骨折的复位、固定和术后康复。     

反义寡核苷酸对脑胶质瘤细胞生长抑制作用的动态研究

目的　探讨原癌基因 c- m yb反义寡核苷酸 (AON)对 C6脑胶质瘤细胞的体内生长抑制作用。方法　将 C6脑胶质瘤细胞接种于裸鼠皮下 ,当肿瘤长至 10 mm左右时随机分成 3组 (每组 12只 ) ,分别用 c- mybAON、正义寡核苷酸 (SON)和生理盐水瘤区原位注射 ,注药后 4、8、12和 16日各组处死动物 3只 ,动态观察肿瘤的体积、重量及病理学改变 ;用流式细胞仪检测肿瘤细胞的凋亡 ;以免疫组化方法分析各组的 c- m yb、bcl- 2蛋白阳性表达率。结果　 c- myb AON组的肿瘤体积抑制率分别为第 4天 6 6 .7% ,第 8天 71.4% ,第 12天 72 % ,第 16天73% ,与对照组相比 ,其生长抑制作用具有显著性 (P<0 .0 5 ) ;AON组凋亡细胞百分率为第 4天 3.4% ,第 8天 2 7.1% ,第 12天 46 .1% ,第 16天 48.4% ,是 SON组和对照组相应时段凋亡细胞的 3.5倍以上 (P<0 .0 5 ) ;AON组 c-myb和 bcl- 2蛋白阳性表达率较对照组有显著降低 (P<0 .0 5 ) ;且 AON治疗后的脑胶质瘤中见较多炎性细胞浸润和钙化灶。结论　 c- myb癌基因有可能成为反义基因治疗恶性脑胶质瘤的优选靶点之一     

Application of network pharmacology and molecular docking to elucidate the potential mechanism of Astragalus–Scorpion against prostate cancer

The present study aimed to investigate the molecular mechanism of the Astragalus–Scorpion drug pair in the treatment of prostate cancer (PCa). We employed network pharmacology and molecular docking technology to retrieving the active ingredients and corresponding targets of Astragalus–Scorpion by using TCMSP, BATMAN-TCM, TCMID and Swiss Target Prediction Databases. The targets related to PCa were retrieved through GeneCards. Cytoscape software was used to construct the ‘active ingredient–target disease’ network, and GO and KEGG enrichment analyses were performed on the common targets. Autodock software was used for molecular docking verification. In total, 26 active ingredients, 340 potential targets related to active ingredients and 122 common targets were screened from Astragalus–Scorpion drug pair. The core targets of the protein–protein interaction (PPI) network were JUN, AKT1, IL6, MAPK1 and RELA, whereas the core active ingredients were quercetin, kaempferol, formononetin, 7-o-methylisomucronulatol and calycosin. Nearly 762 GO entries and 154 pathways were obtained by using the pathway enrichment analysis. Molecular docking results revealed that quercetin and kaempferol bind to AKT1 and formononetin binds to RELA, all of which were found to be stable bounds.     

Pulmonary contusions in patients with rib fractures: The need to better classify a common injury

BackgroundPulmonary contusions are common injuries. Computed tomography reveals vast contused lung volume spectrum, yet pulmonary contusions are defined dichotomously (unilateral vs bilateral). We assessed whether there is stepwise increased risk of pulmonary complications among patients without, with unilateral, and with bilateral pulmonary contusion.MethodsWe identified adults admitted with rib fractures using the largest US inpatient database. After propensity-score-matching patients without vs with unilateral vs bilateral pulmonary contusions and adjusting for residual confounders, we compared risk for pneumonia, ventilator-associated pneumonia (VAP), respiratory failure, intubation, and mortality.ResultsAmong 148,140 encounters of adults with multiple rib fractures, 19% had concomitant pulmonary contusions. Matched patients with pulmonary contusions had increased risk of pneumonia 19% [95%CI:16–33%], respiratory failure 40% [95%CI: 31–50%], and intubation 46% [95%CI: 33–61%]. Delineation showed bilateral contusions, not unilateral contusions, attributed to increased risk of complications.ConclusionsThere is likely a correlation between contused lung volume and risk of pulmonary complications; dichotomously classifying pulmonary contusions is insufficient. Better understanding this correlation requires establishing the clinically significant contusion volume and a correspondingly refined classification system.     

Box-Behnken设计-响应面法优化经典名方四妙勇安汤煎煮工艺研究

目的 遵循中医药传承创新发展的基本准则——“遵古原则”,考察经典名方四妙勇安汤（Simiao Yong’an Decoction,SYD）的煎煮工艺,确保原汤剂原汁原味的传统功效,并进行质量综合评价,为经典名方SYD进一步制剂开发提供参考。方法 采用Box-Behnken设计-响应面法对加水量、浸泡时间、煎煮时间进行考察,通过指纹图谱结合多元统计分析进行定性半定量评价,通过含量测定分析和干膏率进行定量评价,综合以上评价方法优选煎煮工艺并验证。结果 通过Box-Behnken设计-响应面法制备17批煎煮样品,建立了17批样品HPLC指纹图谱,标定了14个共有峰,利用多元统计分析对指纹图谱共有峰数据进行主成分分析（principal component analysis,PCA）与正交偏最小二乘法-判别分析（orthogonal partial least squares-discriminant analysis,OPLS-DA）并计算得分,结果显示9号工艺为最佳煎煮工艺,即煎煮2次,第1次加16倍量水,浸泡30 min,煎煮30 min;第2次加16倍量水,煎煮30 min。同时采用H...     

Differential contribution of the factors determining long-term renal function after partial nephrectomy over time

PurposeTo define how much of renal function was determined by the preserved renal parenchymal volume and the ischemic insult during partial nephrectomy (PN) long after surgery.MethodsWe analyzed the data of 530 consecutive patients who had undergone PN. For all patients, renal function was measured preoperatively and again at 3 postoperative months, then annually using ^99mTc-diethylenetriaminepentaacetic acid renal scan. Perioperative variables potentially affecting the long-term ipsilateral glomerular filtration rate (GFR) and their time-varying contribution were assessed using a linear mixed model.ResultsThe mean preoperative ipsilateral GFR was 42.9 ml/min, which decreased by 27.3% at 3 months but began to recover thereafter continuing until 4 years (Δ% GFR at 1, 2, 3, 4, and 5 years: 22.3%, 18.5%, 14.7%, 10.0%, and 9.6%, respectively). Parenchymal volume reduction and ischemic time were significantly associated with postoperative ipsilateral GFR throughout observation period unvarying with time. Diabetes and proteinuria were not significant determinants of ipsilateral function at 3 months but became significant at 5 years. In multivariate analysis regarding recovery slope, volume reduction (β = ?0.026, SE 0.006, P < 0.0001), preoperative ipsilateral GFR (β = ?0.021, SE 0.007, P = 0.0012), proteinuria (β = ?0.942, SE 0.372, P = 0.0116), and diabetes (β = ?0.396, SE 0.197, P = 0.0447) were independently significant.ConclusionIpsilateral renal function continued to improve until 5 years after PN. Parenchymal volume loss was the major determinant and its impact on long-term ipsilateral renal function remained constant while ischemic time affected early GFR reduction with its impact diminishing over time. Patient-related factors including diabetes and proteinuria gained significance over time and became independent determinants of recovery slope.     

Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events

BackgroundIncreased rates of respiratory adverse events have been observed in people ≥12 years of age with cystic fibrosis homozygous for the Phe508del-CFTR mutation treated with lumacaftor/ivacaftor, particularly in those with percent predicted forced expiratory volume in 1 s (ppFEV₁) of <40%. We evaluated the safety, tolerability, and efficacy of tezacaftor/ivacaftor in people with cystic fibrosis homozygous for Phe508del-CFTR who discontinued lumacaftor/ivacaftor due to treatment-related respiratory signs or symptoms.MethodsParticipants ≥12 years of age with cystic fibrosis homozygous for Phe508del-CFTR with ppFEV₁ of ≥25% and ≤90% were randomized 1:1 and treated with tezacaftor/ivacaftor or placebo for 56 days.ResultsOf 97 participants, 94 (96.9%) completed the study. The primary endpoint was incidence of predefined respiratory adverse events of special interest (chest discomfort, dyspnea, respiration abnormal, asthma, bronchial hyperreactivity, bronchospasm, and wheezing): tezacaftor/ivacaftor, 14.0%; placebo, 21.3%. The adverse events were mild or moderate in severity. None were serious or led to treatment interruption or discontinuation. Overall, the discontinuation rate was similar between groups. The mean (SD) ppFEV₁ at baseline was 44.6% (16.1%) with tezacaftor/ivacaftor and 48.0% (18.1%) with placebo. The posterior mean difference in absolute change in ppFEV₁ from baseline to the average value of days 28 and 56 was 2.7 percentage points with tezacaftor/ivacaftor vs placebo.ConclusionsTezacaftor/ivacaftor was generally safe, well tolerated, and efficacious in people ≥12 years of age with cystic fibrosis homozygous for Phe508del-CFTR with ppFEV₁ of ≥25% and ≤90% who previously discontinued lumacaftor/ivacaftor due to treatment-related respiratory signs or symptoms.